- Home
- LEXX vs BLAC Comparison
LEXX vs BLAC Comparison
Compare LEXX & BLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- BLAC
- Stock Information
- Founded
- LEXX 2004
- BLAC 2020
- Country
- LEXX Canada
- BLAC United States
- Employees
- LEXX N/A
- BLAC N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- BLAC
- Sector
- LEXX Health Care
- BLAC
- Exchange
- LEXX Nasdaq
- BLAC NYSE
- Market Cap
- LEXX 49.3M
- BLAC 44.0M
- IPO Year
- LEXX N/A
- BLAC 2023
- Fundamental
- Price
- LEXX $3.19
- BLAC $10.89
- Analyst Decision
- LEXX Strong Buy
- BLAC
- Analyst Count
- LEXX 2
- BLAC 0
- Target Price
- LEXX $11.00
- BLAC N/A
- AVG Volume (30 Days)
- LEXX 96.5K
- BLAC 502.0
- Earning Date
- LEXX 11-18-2024
- BLAC 01-01-0001
- Dividend Yield
- LEXX N/A
- BLAC N/A
- EPS Growth
- LEXX N/A
- BLAC N/A
- EPS
- LEXX N/A
- BLAC N/A
- Revenue
- LEXX $411,019.00
- BLAC N/A
- Revenue This Year
- LEXX $82.02
- BLAC N/A
- Revenue Next Year
- LEXX $95.09
- BLAC N/A
- P/E Ratio
- LEXX N/A
- BLAC N/A
- Revenue Growth
- LEXX 34.05
- BLAC N/A
- 52 Week Low
- LEXX $0.85
- BLAC $10.39
- 52 Week High
- LEXX $6.85
- BLAC $11.60
- Technical
- Relative Strength Index (RSI)
- LEXX 48.73
- BLAC 61.32
- Support Level
- LEXX $2.91
- BLAC $10.80
- Resistance Level
- LEXX $3.39
- BLAC $10.87
- Average True Range (ATR)
- LEXX 0.20
- BLAC 0.00
- MACD
- LEXX 0.00
- BLAC -0.00
- Stochastic Oscillator
- LEXX 56.00
- BLAC 0.00
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
About BLAC BELLEVUE LIFE SCIENCES ACQ CORP
Bellevue Life Sciences Acquisition Corp is a blank check company.